Overly Aggressive Prialt Dose Data Are Not Surrogate Endpoints, FDA Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Data from failed dosing protocols do not constitute surrogate endpoints, FDA informed Elan in rejecting the company’s bid for accelerated approval of Prialt.
You may also be interested in...
Marine-Based Drugs Face Choppy Waters, But 13 Compounds In Clinical Trials
When an FDA advisory committee voted against approval of Yondelis (trabectedin) for treatment of relapsed ovarian cancer, drug sponsor Centocor/Ortho Biotech wasn't the only one that was disappointed. Researchers focused on marine natural products have been tracking Yondelis, one of the leading sea-based compounds, and its clearance in the U.S. would have been a boon for their field.
Marine-Based Drugs Face Choppy Waters, But 13 Compounds In Clinical Trials
When an FDA advisory committee voted against approval of Yondelis (trabectedin) for treatment of relapsed ovarian cancer, drug sponsor Centocor/Ortho Biotech wasn't the only one that was disappointed. Researchers focused on marine natural products have been tracking Yondelis, one of the leading sea-based compounds, and its clearance in the U.S. would have been a boon for their field
Prialt Review Shows Swing In FDA’s Statistical Preference
FDA reanalyzed Elan's Prialt (ziconotide) data using its now-preferred conservative technique for imputation of missing data in chronic pain trials to assuage concerns that the protocol-specified analysis could magnify treatment effect